**Phase I Program**

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

---

**No Known Mutations**

- **IRB#16804**
  - DCC-3014 in subjects with advanced malignancies

---

**No Known Mutations**

- **IRB#17332**
  - LOXO-101 in adult patients with advanced solid tumors

---

**No Known Mutations**

- **IRB#18498**
  - Study of BA3021 in patients with advanced solid tumors

---

**No Known Mutations**

- **IRB#19377**
  - A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumors

---

**No Known Mutations**

- **IRB#19390**
  - A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

---

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

---

7/20/2020

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)
**Phase I Program**  
Note: Other Phase 1 Studies may be open at the Knight, please click here to view

---

**Tumor Mutation Burden - High**

- **Melanoma**
  - IRB 20920 Study coming soon
  - IRB 20920 Study 02A coming soon
  - IRB 20920 Study 02B coming soon
  - IRB 20920 Study 02C coming soon

**NTRK, ROS1, ALK gene rearrangement**

- IRB#18788 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

**Fusion-NTRK (previously treated)**

- IRB#15206 Entrectinib in Patients with Advanced or Metastatic Solid Tumors

**RET Mutations**

- IRB#17674 Loxo-195 in fusion-NTRK (previously treated) solid tumors
- IRB#16676 BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors
- IRB#18164 A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

**Fusion Proteins Specific**

- BRD Amplifications Specific
- MYC Amplifications Specific
- AR Amplifications Specific

**Folate Receptor Alpha Expression**

- TNBC, HGSOC, Endometrial, and advanced solid tumor with Tp53 mutation

**TNBC, HGSOC, Endometrial, and advanced solid tumor with Tp53 mutation**

- IRB 21548 Study coming soon

---

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

7/20/2020

http://www.ohsu.edu/research/rda/so/knight.php
Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway

CLDN18.2 expressing solid tumors

IRB 21819 coming soon
IRB 21856 coming soon

http://www.ohsu.edu/research/rda/so/knight.php